Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash? Gossamer Bio’s seralutinib did not achieve the predefined statistical bar for its main goal in the phase 3 PROSERA trial.
GOSS Stock Earnings: Gossamer Bio Misses EPS, Misses Revenue for Q2 2024 GOSS stock results show that Gossamer Bio missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says Oppenheimer initiated coverage on Gossamer Bio, highlighting seralutinib's clean long-term safety profile for pulmonary arterial hypertension. Seralutinib shows potential in underserved markets.
The Penny Stock Pundits: 3 Companies Poised to Become the Talk of Wall Street Taking a small position in these penny stocks today could have you sitting on a sizable gain by the time Wall Street starts to pile in.
GOSS Stock Earnings: Gossamer Bio Misses EPS for Q1 2024 GOSS stock results show that Gossamer Bio missed analyst estimates for earnings per share the first quarter of 2024.
Gossamer Bio Collaborates With Italian Drugmaker Chiesi To Advance Lung Health Solutions Worldwide Gossamer Bio partners with Chiesi Farmaceutici to develop and market seralutinib globally, targeting pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
